Assembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
November 05, 2020 16:01 ET
|
Assembly Biosciences, Inc.
- HBV field’s first core inhibitor combination study to assess off-treatment response has not achieved a meaningful rate of sustained virologic response - - Vebicorvir Phase 3 registrational program...
Multiple Abstracts Highlighting Assembly Biosciences’ Hepatitis B Core Inhibitor Development Programs Accepted for Presentation at the 2020 AASLD The Liver Meeting Digital Experience™
November 02, 2020 08:00 ET
|
Assembly Biosciences, Inc.
- Four posters, including two late breaking, will include new clinical and preclinical data on Assembly Bio’s hepatitis B virus (HBV) core inhibitor portfolio SOUTH SAN FRANCISCO, Calif., Nov. 02,...
Assembly Biosciences Appoints Gina Consylman to Board of Directors
October 20, 2020 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact Award
October 15, 2020 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Announces October Conference Participation
October 05, 2020 07:30 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2020 16:30 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2020 16:30 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020
August 28, 2020 06:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2020 16:30 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
August 05, 2020 16:05 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...